US FDA explains risk-based monitoring of clinical trials for drug and device sponsors
This article was originally published in Clinica
Executive Summary
The US FDA has issued a draft guideline to help sponsors develop risk-based monitoring strategies and plans for clinical investigations of drugs, biologics, medical devices and combination products.